Anthony Petrone
Stock Analyst at Mizuho
(3.85)
# 576
Out of 4,853 analysts
170
Total ratings
50%
Success rate
8.23%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EMBC Embecta | Maintains: Neutral | $15 → $13 | $10.40 | +25.00% | 2 | May 23, 2025 | |
| MDT Medtronic | Maintains: Outperform | $100 → $98 | $85.60 | +14.49% | 5 | May 22, 2025 | |
| GKOS Glaukos | Maintains: Outperform | $200 → $175 | $90.96 | +92.39% | 8 | Apr 16, 2025 | |
| GH Guardant Health | Initiates: Outperform | $55 | $47.76 | +15.16% | 1 | Apr 10, 2025 | |
| SENS Senseonics Holdings | Initiates: Outperform | $2 | $0.53 | +273.90% | 1 | Apr 10, 2025 | |
| TNDM Tandem Diabetes Care | Initiates: Neutral | $20 | $20.18 | -0.89% | 1 | Apr 10, 2025 | |
| DXCM DexCom | Initiates: Outperform | $85 | $85.61 | -0.71% | 1 | Apr 10, 2025 | |
| EXAS Exact Sciences | Initiates: Outperform | $60 | $55.17 | +8.75% | 1 | Apr 10, 2025 | |
| ALC Alcon | Maintains: Outperform | $115 → $120 | $85.94 | +39.63% | 9 | Mar 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $54 → $58 | $42.65 | +35.99% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $60 | $44.50 | +34.83% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $87 | $62.57 | +39.04% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $275 → $250 | $122.75 | +103.67% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $110 | $102.43 | +7.39% | 8 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $115 → $130 | $132.96 | -2.23% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $20.33 | -31.14% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $70 | $37.09 | +88.73% | 6 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $16.67 | +229.93% | 7 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $100 | $79.63 | +25.58% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $71.13 | +47.62% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $105 | $77.85 | +34.87% | 7 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 | $249.94 | -13.98% | 15 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 | $137.91 | +81.28% | 6 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $6.42 | +118.07% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $103 → $115 | $67.42 | +70.57% | 14 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $557.95 | -30.10% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $82.55 | -18.84% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $115 | $69.66 | +65.09% | 14 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $91.46 | +91.34% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $8.26 | +202.85% | 3 | May 13, 2020 | |
Embecta
May 23, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $10.40
Upside: +25.00%
Medtronic
May 22, 2025
Maintains: Outperform
Price Target: $100 → $98
Current: $85.60
Upside: +14.49%
Glaukos
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $90.96
Upside: +92.39%
Guardant Health
Apr 10, 2025
Initiates: Outperform
Price Target: $55
Current: $47.76
Upside: +15.16%
Senseonics Holdings
Apr 10, 2025
Initiates: Outperform
Price Target: $2
Current: $0.53
Upside: +273.90%
Tandem Diabetes Care
Apr 10, 2025
Initiates: Neutral
Price Target: $20
Current: $20.18
Upside: -0.89%
DexCom
Apr 10, 2025
Initiates: Outperform
Price Target: $85
Current: $85.61
Upside: -0.71%
Exact Sciences
Apr 10, 2025
Initiates: Outperform
Price Target: $60
Current: $55.17
Upside: +8.75%
Alcon
Mar 28, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $85.94
Upside: +39.63%
Tarsus Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $42.65
Upside: +35.99%
Feb 26, 2025
Maintains: Outperform
Price Target: $70 → $60
Current: $44.50
Upside: +34.83%
Nov 5, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $62.57
Upside: +39.04%
Nov 1, 2024
Maintains: Neutral
Price Target: $275 → $250
Current: $122.75
Upside: +103.67%
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $102.43
Upside: +7.39%
Oct 17, 2024
Maintains: Neutral
Price Target: $115 → $130
Current: $132.96
Upside: -2.23%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $20.33
Upside: -31.14%
Jun 6, 2024
Maintains: Buy
Price Target: $65 → $70
Current: $37.09
Upside: +88.73%
May 8, 2024
Maintains: Buy
Price Target: $53 → $55
Current: $16.67
Upside: +229.93%
May 3, 2024
Maintains: Buy
Price Target: $90 → $100
Current: $79.63
Upside: +25.58%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $71.13
Upside: +47.62%
Apr 11, 2024
Maintains: Buy
Price Target: $95 → $105
Current: $77.85
Upside: +34.87%
Mar 27, 2024
Maintains: Buy
Price Target: $215
Current: $249.94
Upside: -13.98%
Mar 27, 2024
Maintains: Buy
Price Target: $250
Current: $137.91
Upside: +81.28%
Mar 1, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $6.42
Upside: +118.07%
Mar 1, 2024
Maintains: Buy
Price Target: $103 → $115
Current: $67.42
Upside: +70.57%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $557.95
Upside: -30.10%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $82.55
Upside: -18.84%
Feb 8, 2023
Maintains: Buy
Price Target: $110 → $115
Current: $69.66
Upside: +65.09%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $91.46
Upside: +91.34%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $8.26
Upside: +202.85%